Pfizer Inc. (PFE)
NYSE: PFE · Real-Time Price · USD
26.21
+0.04 (0.15%)
At close: Jun 12, 2026, 4:00 PM EDT
26.19
-0.02 (-0.08%)
After-hours: Jun 12, 2026, 7:59 PM EDT
Revenue
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Quarter | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 | Q4 2020 | Q3 2020 | Q2 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 29, 2026 | Dec '25 Dec 31, 2025 | Sep '25 Sep 28, 2025 | Jun '25 Jun 29, 2025 | Mar '25 Mar 30, 2025 | Dec '24 Dec 31, 2024 | Sep '24 Sep 29, 2024 | Jun '24 Jun 30, 2024 | Mar '24 Mar 31, 2024 | Dec '23 Dec 31, 2023 | Oct '23 Oct 1, 2023 | Jul '23 Jul 2, 2023 | Apr '23 Apr 2, 2023 | Dec '22 Dec 31, 2022 | Oct '22 Oct 2, 2022 | Jul '22 Jul 3, 2022 | Apr '22 Apr 3, 2022 | Dec '21 Dec 31, 2021 | Oct '21 Oct 3, 2021 | Jul '21 Jul 4, 2021 | Apr '21 Apr 4, 2021 | Dec '20 Dec 31, 2020 | Sep '20 Sep 27, 2020 | Jun '20 Jun 28, 2020 |
Primary Care Revenue | 5.54B | |||||||||||||||||||||||
Primary Care Revenue Growth | -2.63% | |||||||||||||||||||||||
Global Pharmaceuticals Business (Biopharma) Revenue | 14.16B | |||||||||||||||||||||||
Global Pharmaceuticals Business (Biopharma) Revenue Growth | 5.36% | |||||||||||||||||||||||
Business Innovation (Pfizer CentreOne) Revenue | 289.00M | |||||||||||||||||||||||
Business Innovation (Pfizer CentreOne) Revenue Growth | 5.86% | |||||||||||||||||||||||
Revenue (Other) | 1.00M | |||||||||||||||||||||||
Revenue (Total) | 14.45B | |||||||||||||||||||||||
Revenue (Total) Growth | 5.37% |
Revenue by Geography
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Quarter | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 | Q4 2020 | Q3 2020 | Q2 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 29, 2026 | Dec '25 Dec 31, 2025 | Sep '25 Sep 28, 2025 | Jun '25 Jun 29, 2025 | Mar '25 Mar 30, 2025 | Dec '24 Dec 31, 2024 | Sep '24 Sep 29, 2024 | Jun '24 Jun 30, 2024 | Mar '24 Mar 31, 2024 | Dec '23 Dec 31, 2023 | Oct '23 Oct 1, 2023 | Jul '23 Jul 2, 2023 | Apr '23 Apr 2, 2023 | Dec '22 Dec 31, 2022 | Oct '22 Oct 2, 2022 | Jul '22 Jul 3, 2022 | Apr '22 Apr 3, 2022 | Dec '21 Dec 31, 2021 | Oct '21 Oct 3, 2021 | Jul '21 Jul 4, 2021 | Apr '21 Apr 4, 2021 | Dec '20 Dec 31, 2020 | Sep '20 Sep 27, 2020 | Jun '20 Jun 28, 2020 |
United States Revenue | 8.73B | |||||||||||||||||||||||
United States Revenue Growth | 4.26% | |||||||||||||||||||||||
Developed Markets Revenue | 3.43B | |||||||||||||||||||||||
Developed Markets Revenue Growth | 7.80% | |||||||||||||||||||||||
Emerging Markets Revenue (Post-FY2023 Reporting) | 2.29B | |||||||||||||||||||||||
Emerging Markets Revenue (Post-FY2023 Reporting) Growth | 6.01% | |||||||||||||||||||||||
Revenue (Other) | 1.00M | |||||||||||||||||||||||
Revenue (Total) | 14.45B | |||||||||||||||||||||||
Revenue (Total) Growth | 5.37% |
Revenue by Geography 2
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Quarter | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 | Q4 2020 | Q3 2020 | Q2 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 29, 2026 | Dec '25 Dec 31, 2025 | Sep '25 Sep 28, 2025 | Jun '25 Jun 29, 2025 | Mar '25 Mar 30, 2025 | Dec '24 Dec 31, 2024 | Sep '24 Sep 29, 2024 | Jun '24 Jun 30, 2024 | Mar '24 Mar 31, 2024 | Dec '23 Dec 31, 2023 | Oct '23 Oct 1, 2023 | Jul '23 Jul 2, 2023 | Apr '23 Apr 2, 2023 | Dec '22 Dec 31, 2022 | Oct '22 Oct 2, 2022 | Jul '22 Jul 3, 2022 | Apr '22 Apr 3, 2022 | Dec '21 Dec 31, 2021 | Oct '21 Oct 3, 2021 | Jul '21 Jul 4, 2021 | Apr '21 Apr 4, 2021 | Dec '20 Dec 31, 2020 | Sep '20 Sep 27, 2020 | Jun '20 Jun 28, 2020 |
United States Revenue | 8.73B | |||||||||||||||||||||||
United States Revenue Growth | 4.26% | |||||||||||||||||||||||
Revenue (Total) | 14.45B | |||||||||||||||||||||||
Revenue (Total) Growth | 5.37% |
Revenue by Geography 3
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Quarter | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 | Q4 2020 | Q3 2020 | Q2 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 29, 2026 | Dec '25 Dec 31, 2025 | Sep '25 Sep 28, 2025 | Jun '25 Jun 29, 2025 | Mar '25 Mar 30, 2025 | Dec '24 Dec 31, 2024 | Sep '24 Sep 29, 2024 | Jun '24 Jun 30, 2024 | Mar '24 Mar 31, 2024 | Dec '23 Dec 31, 2023 | Oct '23 Oct 1, 2023 | Jul '23 Jul 2, 2023 | Apr '23 Apr 2, 2023 | Dec '22 Dec 31, 2022 | Oct '22 Oct 2, 2022 | Jul '22 Jul 3, 2022 | Apr '22 Apr 3, 2022 | Dec '21 Dec 31, 2021 | Oct '21 Oct 3, 2021 | Jul '21 Jul 4, 2021 | Apr '21 Apr 4, 2021 | Dec '20 Dec 31, 2020 | Sep '20 Sep 27, 2020 | Jun '20 Jun 28, 2020 |
United States Revenue | 8.73B | |||||||||||||||||||||||
United States Revenue Growth | 4.26% | |||||||||||||||||||||||
International Revenue | 5.72B | |||||||||||||||||||||||
International Revenue Growth | 7.08% | |||||||||||||||||||||||
Revenue (Total) | 14.45B | |||||||||||||||||||||||
Revenue (Total) Growth | 5.37% |
EBT
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Quarter | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 | Q4 2020 | Q3 2020 | Q2 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 29, 2026 | Dec '25 Dec 31, 2025 | Sep '25 Sep 28, 2025 | Jun '25 Jun 29, 2025 | Mar '25 Mar 30, 2025 | Dec '24 Dec 31, 2024 | Sep '24 Sep 29, 2024 | Jun '24 Jun 30, 2024 | Mar '24 Mar 31, 2024 | Dec '23 Dec 31, 2023 | Oct '23 Oct 1, 2023 | Jul '23 Jul 2, 2023 | Apr '23 Apr 2, 2023 | Dec '22 Dec 31, 2022 | Oct '22 Oct 2, 2022 | Jul '22 Jul 3, 2022 | Apr '22 Apr 3, 2022 | Dec '21 Dec 31, 2021 | Oct '21 Oct 3, 2021 | Jul '21 Jul 4, 2021 | Apr '21 Apr 4, 2021 | Dec '20 Dec 31, 2020 | Sep '20 Sep 27, 2020 | Jun '20 Jun 28, 2020 |
Global Pharmaceuticals Business (Biopharma) Earnings | 6.84B | |||||||||||||||||||||||
Global Pharmaceuticals Business (Biopharma) Earnings Growth | -3.27% | |||||||||||||||||||||||
Other Business Activities Earnings | -1.67B |
Key Performance Indicators
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Quarter | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 | Q4 2020 | Q3 2020 | Q2 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 29, 2026 | Dec '25 Dec 31, 2025 | Sep '25 Sep 28, 2025 | Jun '25 Jun 29, 2025 | Mar '25 Mar 30, 2025 | Dec '24 Dec 31, 2024 | Sep '24 Sep 29, 2024 | Jun '24 Jun 30, 2024 | Mar '24 Mar 31, 2024 | Dec '23 Dec 31, 2023 | Oct '23 Oct 1, 2023 | Jul '23 Jul 2, 2023 | Apr '23 Apr 2, 2023 | Dec '22 Dec 31, 2022 | Oct '22 Oct 2, 2022 | Jul '22 Jul 3, 2022 | Apr '22 Apr 3, 2022 | Dec '21 Dec 31, 2021 | Oct '21 Oct 3, 2021 | Jul '21 Jul 4, 2021 | Apr '21 Apr 4, 2021 | Dec '20 Dec 31, 2020 | Sep '20 Sep 27, 2020 | Jun '20 Jun 28, 2020 |
Comirnaty Direct Sales and Alliance Revenue | 232.00M | |||||||||||||||||||||||
Comirnaty Direct Sales and Alliance Revenue Growth | -58.94% | |||||||||||||||||||||||
Eliquis Alliance Revenue and Direct Sales | 2.17B | |||||||||||||||||||||||
Eliquis Alliance Revenue and Direct Sales Growth | 12.64% | |||||||||||||||||||||||
Paxlovid Revenue | 186.00M | |||||||||||||||||||||||
Paxlovid Revenue Growth | -62.12% | |||||||||||||||||||||||
Prevnar Family Revenue | 1.69B | |||||||||||||||||||||||
Prevnar Family Revenue Growth | 1.81% | |||||||||||||||||||||||
Nurtec ODT/Vydura Revenue | 353.00M | |||||||||||||||||||||||
Nurtec ODT/Vydura Revenue Growth | 42.34% | |||||||||||||||||||||||
Abrysvo Revenue | 180.00M | |||||||||||||||||||||||
Abrysvo Revenue Growth | 37.41% | |||||||||||||||||||||||
Vyndaqel Family Revenue | 1.60B | |||||||||||||||||||||||
Vyndaqel Family Revenue Growth | 7.81% | |||||||||||||||||||||||
Xeljanz Revenue | 180.00M | |||||||||||||||||||||||
Xeljanz Revenue Growth | 40.63% | |||||||||||||||||||||||
Ibrance Revenue | 1.01B | |||||||||||||||||||||||
Ibrance Revenue Growth | 3.17% |